RFP
ELDN icon

Root Financial Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Root Financial Partners’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110
Closed -$339 – 1224
2026
Q1 		$339 Buy
+110
New +$259 ﹤0.01% 2988

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Root Financial Partners's ELDN Position: Q2 2026 in Review

Root Financial Partners sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 110 shares — an estimated $339 sold.

Root Financial Partners first reported a position in ELDN in Q1 2026 and held it in 1 quarter. The position peaked at $339 in Q1 2026. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Root Financial Partners reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 110 Eledon Pharmaceuticals shares in Q2 2026, an estimated $339.
  • Root Financial Partners first reported a position in Eledon Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Eledon Pharmaceuticals position peaked at $339 in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.